To provide the information your oncologist is not telling you or doesn't have the time to!
Empowering Hope: A Breakthrough in CLL/SLL Treatment On December 1, 2023, the Food and Drug Administration (FDA) delivered a beacon of hope by granting accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company). This approval is a significant stride in the treatment landscape for adults facing chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) …
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
This message comes from Ashlee Jones, our dedicated nurse navigator specializing in melanoma and sarcoma. She is held in high regard by our entire team, including nurses, pharmacists, staff, research professionals, and physicians! I’ve consistently believed that patients newly diagnosed with cancer may face a challenging beginning to their journey, given the unfamiliar diagnosis, the …
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …
This post is dedicated to all the hard working oncology nurses! In cancer care, oncology nurses are often the unsung heroes, playing a myriad of roles that go beyond traditional nursing responsibilities. This post celebrates these compassionate caregivers, shedding light on the multifaceted roles they play in the journey of a cancer patient. 1. Patient …
Cancer screening has witnessed a transformative evolution, with technological advancements paving the way for more effective and less invasive methods. In this article, we will explore the integration of liquid biopsies as a groundbreaking approach to early cancer detection. This non-invasive method holds immense potential in detecting genetic alterations and circulating tumor DNA, ushering in …
In a groundbreaking development for patients with progressing desmoid tumors, the Food and Drug Administration (FDA) has granted approval for nirogacestat, a novel treatment provided by SpringWorks Therapeutics, Inc. This approval marks a significant milestone as the first-ever sanctioned therapy for desmoid tumors, offering hope and a new avenue of treatment for affected individuals. Let’s …
In the realm of oncology, antibiotics assume a nuanced, yet critical role. They stand as guardians against bacterial threats, but wield a double-edged sword when it comes to their interaction with cancer treatments and the patient’s microbiome. This piece aims to untangle the complexities of antibiotic use in cancer care, highlighting how they operate, when …
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …